-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Keyuan Pharmaceutical
A leading enterprise in a specific segment of the domestic chemical API market, with over 20 years of deep industry expertise.
Driven by the integrated innovation of chemical and biosynthetic technologies.
Continuously strengthen core competencies in chronic disease areas such as glycemic control and cardiovascular health, expand into emerging fields including cosmetic raw materials, high-end pharmaceutical excipients, and functional food additives, and build an industrial ecosystem characterized by “active pharmaceutical ingredients plus cross‑sectoral synergy.”
Focusing on the integration of APIs and finished dosage forms, as well as excipients and finished dosage forms.
The core product has obtained certifications from multiple regulatory authorities, including the U.S. FDA, the EU’s CEP, Japan’s PMDA, and South Korea’s MFDS.
Our collaborative clients span more than twenty countries and regions worldwide.
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline